	US 11,815,509 B2
	Cell line and uses thereof
Malin Marie Lindstedt, Sodra Sandby (SE); Carl A K Borrebaeck, Lund (SE); Henrik Johansson, Malmo (SE); and Robin Gradin, Tjornarp (SE)
Assigned to SENZAGEN AB, Lund (SE)
Appl. No. 16/644,808
Filed by SENZAGEN AB, Lund (SE)
PCT Filed Sep. 24, 2018, PCT No. PCT/EP2018/075829 § 371(c)(1), (2) Date Mar. 5, 2020, PCT Pub. No. WO2019/057977, PCT Pub. Date Mar. 28, 2019.
Claims priority of application No. 1715445 (GB), filed on Sep. 25, 2017.
Prior Publication US 2022/0178913 A1, Jun. 9, 2022
Int. Cl. G01N 33/50 (2006.01); C12N 5/09 (2010.01); C12Q 1/6876 (2018.01)

CPC G01N 33/5044 (2013.01) [C12N 5/0694 (2013.01); C12Q 1/6876 (2013.01); G01N 33/5023 (2013.01); C12Q 2600/158 (2013.01)]

2 Claims

1. A non-naturally occurring dendritic-like myeloid leukaemia cell according to ATCC Patent Deposit Designation PTA-123875.